Nature Reviews Rheumatology最新文献

筛选
英文 中文
Advancing precision rheumatology through tissue and blood profiling 通过组织和血液分析推进精准风湿病学的发展
IF 29.4 1区 医学
Nature Reviews Rheumatology Pub Date : 2024-04-12 DOI: 10.1038/s41584-024-01115-7
George D. Kalliolias, Athanasios G. Papavassiliou
{"title":"Advancing precision rheumatology through tissue and blood profiling","authors":"George D. Kalliolias, Athanasios G. Papavassiliou","doi":"10.1038/s41584-024-01115-7","DOIUrl":"10.1038/s41584-024-01115-7","url":null,"abstract":"Multidimensional and single-cell profiling of peripheral blood and inflamed tissues is a powerful and high-resolution tool for the stratification of patients with autoimmune rheumatic diseases into distinct cellular and/or molecular endotypes. The road towards precision rheumatology is long, but the time has come to enter the territory of clinical validation.","PeriodicalId":18810,"journal":{"name":"Nature Reviews Rheumatology","volume":null,"pages":null},"PeriodicalIF":29.4,"publicationDate":"2024-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140550600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Molecular biomarker approaches to prevention of post-traumatic osteoarthritis 预防创伤后骨关节炎的分子生物标记方法
IF 33.7 1区 医学
Nature Reviews Rheumatology Pub Date : 2024-04-11 DOI: 10.1038/s41584-024-01102-y
Virginia Byers Kraus, Ming-Feng Hsueh
{"title":"Molecular biomarker approaches to prevention of post-traumatic osteoarthritis","authors":"Virginia Byers Kraus, Ming-Feng Hsueh","doi":"10.1038/s41584-024-01102-y","DOIUrl":"10.1038/s41584-024-01102-y","url":null,"abstract":"Up to 50% of individuals develop post-traumatic osteoarthritis (PTOA) within 10 years following knee-joint injuries such as anterior cruciate ligament rupture or acute meniscal tear. Lower-extremity PTOA prevalence is estimated to account for ≥12% of all symptomatic osteoarthritis (OA), or approximately 5.6 million cases in the USA. With knowledge of the inciting event, it might be possible to ‘catch PTOA in the act’ with sensitive imaging and soluble biomarkers and thereby prevent OA sequelae by early intervention. Existing biomarker data in the joint-injury literature can provide insights into the pathogenesis and early risk trajectory related to PTOA and can help to elucidate a research agenda for preventing or slowing the onset of PTOA. Non-traumatic OA and PTOA have many clinical, radiological and genetic similarities, and efforts to understand early risk trajectories in PTOA might therefore contribute to the identification and classification of early non-traumatic OA, which is the most prevalent form of OA. Early identification of osteoarthritis (OA) prior to the development of symptoms is challenging. Post-traumatic OA provides a model for the development of OA following a defined event. In this Review, the authors describe the existing knowledge relating to the biomarkers of post-traumatic OA, which might also be applicable to the identification of early non-traumatic OA.","PeriodicalId":18810,"journal":{"name":"Nature Reviews Rheumatology","volume":null,"pages":null},"PeriodicalIF":33.7,"publicationDate":"2024-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140544740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Joint-specific memory, resident memory T cells and the rolling window of opportunity in arthritis 关节特异性记忆、常驻记忆 T 细胞和关节炎的滚动机会之窗
IF 33.7 1区 医学
Nature Reviews Rheumatology Pub Date : 2024-04-10 DOI: 10.1038/s41584-024-01107-7
Margaret H. Chang, Robert C. Fuhlbrigge, Peter A. Nigrovic
{"title":"Joint-specific memory, resident memory T cells and the rolling window of opportunity in arthritis","authors":"Margaret H. Chang, Robert C. Fuhlbrigge, Peter A. Nigrovic","doi":"10.1038/s41584-024-01107-7","DOIUrl":"10.1038/s41584-024-01107-7","url":null,"abstract":"In rheumatoid arthritis, juvenile idiopathic arthritis and other forms of inflammatory arthritis, the immune system targets certain joints but not others. The pattern of joints affected varies by disease and by individual, with flares most commonly involving joints that were previously inflamed. This phenomenon, termed joint-specific memory, is difficult to explain by systemic immunity alone. Mechanisms of joint-specific memory include the involvement of synovial resident memory T cells that remain in the joint during remission and initiate localized disease recurrence. In addition, arthritis-induced durable changes in synovial fibroblasts and macrophages can amplify inflammation in a site-specific manner. Together with ongoing systemic processes that promote extension of arthritis to new joints, these local factors set the stage for a stepwise progression in disease severity, a paradigm for arthritis chronicity that we term the joint accumulation model. Although durable drug-free remission through early treatment remains elusive for most forms of arthritis, the joint accumulation paradigm defines new therapeutic targets, emphasizes the importance of sustained treatment to prevent disease extension to new joints, and identifies a rolling window of opportunity for altering the natural history of arthritis that extends well beyond the initiation phase of disease. This Review discusses joint-specific memory (the tendency of arthritis to recur in previously inflamed joints), explores the involvement of resident memory T cells and other contributors, and evaluates how arthritis might spread to new joints, emphasizing the important of sustained treatment.","PeriodicalId":18810,"journal":{"name":"Nature Reviews Rheumatology","volume":null,"pages":null},"PeriodicalIF":33.7,"publicationDate":"2024-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140545057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Benralizumab noninferior to mepolizumab for EGPA 本拉珠单抗治疗 EGPA 的疗效不劣于麦泊珠单抗
IF 33.7 1区 医学
Nature Reviews Rheumatology Pub Date : 2024-04-09 DOI: 10.1038/s41584-024-01116-6
Sarah Onuora
{"title":"Benralizumab noninferior to mepolizumab for EGPA","authors":"Sarah Onuora","doi":"10.1038/s41584-024-01116-6","DOIUrl":"10.1038/s41584-024-01116-6","url":null,"abstract":"In a head-to-head phase III trial of two drugs that target IL-5 or its receptor, benralizumab was noninferior to mepolizumab for the induction of remission in patients with eosinophilic granulomatosis with polyangiitis.","PeriodicalId":18810,"journal":{"name":"Nature Reviews Rheumatology","volume":null,"pages":null},"PeriodicalIF":33.7,"publicationDate":"2024-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140538278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Author Correction: Therapeutic potential in rheumatic diseases of extracellular vesicles derived from mesenchymal stromal cells 作者更正:源自间充质基质细胞的细胞外囊泡对风湿病的治疗潜力。
IF 33.7 1区 医学
Nature Reviews Rheumatology Pub Date : 2024-04-05 DOI: 10.1038/s41584-024-01114-8
Giuliana Minani Bertolino, Marie Maumus, Christian Jorgensen, Danièle Noël
{"title":"Author Correction: Therapeutic potential in rheumatic diseases of extracellular vesicles derived from mesenchymal stromal cells","authors":"Giuliana Minani Bertolino, Marie Maumus, Christian Jorgensen, Danièle Noël","doi":"10.1038/s41584-024-01114-8","DOIUrl":"10.1038/s41584-024-01114-8","url":null,"abstract":"","PeriodicalId":18810,"journal":{"name":"Nature Reviews Rheumatology","volume":null,"pages":null},"PeriodicalIF":33.7,"publicationDate":"2024-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41584-024-01114-8.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140868977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Author Correction: Proposals for the rheumatological use of JAK inhibitors 作者更正:关于在风湿病中使用 JAK 抑制剂的建议
IF 33.7 1区 医学
Nature Reviews Rheumatology Pub Date : 2024-04-02 DOI: 10.1038/s41584-024-01112-w
Francesco Ciccia, Roberto Caporali
{"title":"Author Correction: Proposals for the rheumatological use of JAK inhibitors","authors":"Francesco Ciccia, Roberto Caporali","doi":"10.1038/s41584-024-01112-w","DOIUrl":"10.1038/s41584-024-01112-w","url":null,"abstract":"","PeriodicalId":18810,"journal":{"name":"Nature Reviews Rheumatology","volume":null,"pages":null},"PeriodicalIF":33.7,"publicationDate":"2024-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41584-024-01112-w.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140648278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Time for a new approach to drug development for rare systemic autoinflammatory diseases 采用新方法开发治疗罕见系统性自身炎症疾病药物的时机已到
IF 33.7 1区 医学
Nature Reviews Rheumatology Pub Date : 2024-04-02 DOI: 10.1038/s41584-024-01108-6
Natalie M. Zitoun, Erkan Demirkaya, Raphaela Goldbach-Mansky, Micol Romano
{"title":"Time for a new approach to drug development for rare systemic autoinflammatory diseases","authors":"Natalie M. Zitoun, Erkan Demirkaya, Raphaela Goldbach-Mansky, Micol Romano","doi":"10.1038/s41584-024-01108-6","DOIUrl":"10.1038/s41584-024-01108-6","url":null,"abstract":"Despite the transformative potential of treatments for systemic autoinflammatory diseases, these conditions remain underfunded and understudied. Urgent, coordinated action among stakeholders is needed to overcome regulatory and research barriers, as is innovation and advocacy for the development of effective therapies for these rare diseases.","PeriodicalId":18810,"journal":{"name":"Nature Reviews Rheumatology","volume":null,"pages":null},"PeriodicalIF":33.7,"publicationDate":"2024-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140349602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Author Correction: International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiative 作者更正:特发性炎症性肌病相关癌症筛查国际指南:国际肌炎评估和临床研究小组(IMACS)倡议。
IF 33.7 1区 医学
Nature Reviews Rheumatology Pub Date : 2024-03-28 DOI: 10.1038/s41584-024-01111-x
Alexander G. S. Oldroyd, Jeffrey P. Callen, Hector Chinoy, Lorinda Chung, David Fiorentino, Patrick Gordon, Pedro M. Machado, Neil McHugh, Albert Selva-O’Callaghan, Jens Schmidt, Sarah L. Tansley, Ruth Ann Vleugels, Victoria P. Werth, International Myositis Assessment and Clinical Studies Group Cancer Screening Expert Group, Rohit Aggarwal
{"title":"Author Correction: International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiative","authors":"Alexander G. S. Oldroyd, Jeffrey P. Callen, Hector Chinoy, Lorinda Chung, David Fiorentino, Patrick Gordon, Pedro M. Machado, Neil McHugh, Albert Selva-O’Callaghan, Jens Schmidt, Sarah L. Tansley, Ruth Ann Vleugels, Victoria P. Werth, International Myositis Assessment and Clinical Studies Group Cancer Screening Expert Group, Rohit Aggarwal","doi":"10.1038/s41584-024-01111-x","DOIUrl":"10.1038/s41584-024-01111-x","url":null,"abstract":"","PeriodicalId":18810,"journal":{"name":"Nature Reviews Rheumatology","volume":null,"pages":null},"PeriodicalIF":33.7,"publicationDate":"2024-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41584-024-01111-x.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140318720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Low-frequency and rare genetic variants associated with rheumatoid arthritis risk 与类风湿性关节炎风险相关的低频和罕见基因变异
IF 33.7 1区 医学
Nature Reviews Rheumatology Pub Date : 2024-03-27 DOI: 10.1038/s41584-024-01096-7
Vanessa L. Kronzer, Jeffrey A. Sparks, Soumya Raychaudhuri, James R. Cerhan
{"title":"Low-frequency and rare genetic variants associated with rheumatoid arthritis risk","authors":"Vanessa L. Kronzer, Jeffrey A. Sparks, Soumya Raychaudhuri, James R. Cerhan","doi":"10.1038/s41584-024-01096-7","DOIUrl":"10.1038/s41584-024-01096-7","url":null,"abstract":"Rheumatoid arthritis (RA) has an estimated heritability of nearly 50%, which is particularly high in seropositive RA. HLA alleles account for a large proportion of this heritability, in addition to many common single-nucleotide polymorphisms with smaller individual effects. Low-frequency and rare variants, such as those captured by next-generation sequencing, can also have a large role in heritability in some individuals. Rare variant discovery has informed the development of drugs such as inhibitors of PCSK9 and Janus kinases. Some 34 low-frequency and rare variants are currently associated with RA risk. One variant (19:10352442G>C in TYK2) was identified in five separate studies, and might therefore represent a promising therapeutic target. Following a set of best practices in future studies, including studying diverse populations, using large sample sizes, validating RA and serostatus, replicating findings, adjusting for other variants and performing functional assessment, could help to ensure the relevance of identified variants. Exciting opportunities are now on the horizon for genetics in RA, including larger datasets and consortia, whole-genome sequencing and direct applications of findings in the management, and especially treatment, of RA. Rheumatoid arthritis has a substantial genetic component, some of which is associated with the presence of low-frequency or rare variants. Next-generation sequencing in large and well-defined cohorts can continue to identify these variants and thereby contribute to the future prediction, diagnosis and treatment of rheumatoid arthritis.","PeriodicalId":18810,"journal":{"name":"Nature Reviews Rheumatology","volume":null,"pages":null},"PeriodicalIF":33.7,"publicationDate":"2024-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140303657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reply to: Current classification criteria underestimate the incidence of idiopathic inflammatory myopathies by ignoring subgroups 答复目前的分类标准忽略了亚群,从而低估了特发性炎症性肌病的发病率。
IF 33.7 1区 医学
Nature Reviews Rheumatology Pub Date : 2024-03-21 DOI: 10.1038/s41584-024-01106-8
Thomas Khoo, James B. Lilleker, Bernard Yu-Hor Thong, Valérie Leclair, Janine A. Lamb, Hector Chinoy
{"title":"Reply to: Current classification criteria underestimate the incidence of idiopathic inflammatory myopathies by ignoring subgroups","authors":"Thomas Khoo, James B. Lilleker, Bernard Yu-Hor Thong, Valérie Leclair, Janine A. Lamb, Hector Chinoy","doi":"10.1038/s41584-024-01106-8","DOIUrl":"10.1038/s41584-024-01106-8","url":null,"abstract":"","PeriodicalId":18810,"journal":{"name":"Nature Reviews Rheumatology","volume":null,"pages":null},"PeriodicalIF":33.7,"publicationDate":"2024-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41584-024-01106-8.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140184897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信